Beyond animal models, low-dose recombinant IL-2 can effectively increase the number of circulating Tregs in humans and exert anti-inflammatory effects, as shown in multiple clinical trials in autoimmunity and in GVHD. This evidence concerns the gene IL2 and graft versus host disease.